FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 579 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients... April 23, 2025 FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma May 20, 2026 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Woman Suffers Seizure And Dies After Making Fatal Error With Her... May 3, 2019 Load more HOT NEWS Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... A New Online Tool Predicts RFS and OS Probabilities in Patients... FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction... Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of...
